

- The INTENSIFY study (Controlled-trials.com #ISRCTN12600624) evaluated the effect of ivabradine treatment on heart failure symptoms and quality of life in clinical practice.
- Resting heart rate, heart failure symptoms (New York Heart Association class, signs of decompensation), left ventricular ejection fraction, brain natriuretic peptide levels, quality of life, and concomitant medication were documented.
- The study duration was 4 months with patients being on optimized medical standard therapy for chronic systolic heart failure at baseline.
- After 4 months ivabradine effectively reduced symptoms and improved quality of life with good general tolerability of the drug.

This summary slide represents the opinions of the authors. Sponsorship for this study and article processing charges was funded by Servier Deutschland GmbH, Munich, Germany. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).